Dr. Malhotra is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1000 FivePoint
Irvine, CA 92618Phone+1 949-671-4673
Education & Training
MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 2006 - 2009
Maulana Azad Medical CollegeClass of 2005
Certifications & Licensure
CA State Medical License 2022 - 2026
NY State Medical License 2010 - 2026
NJ State Medical License 2015 - 2023
DC State Medical License 2006 - 2009
PA State Medical License 2009 - 2009- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Start of enrollment: 2011 Nov 23
- First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors Start of enrollment: 2017 May 04
- Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy Start of enrollment: 2020 Apr 16
- Join now to see all
Publications & Presentations
PubMed
- 483 citationsRisk factors for lung cancer worldwideJyoti Malhotra, Matteo Malvezzi, Eva Negri, Carlo La Vecchia, Paolo Boffetta
The European Respiratory Journal. 2016-09-01 - 130 citationsReal-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.M Palmeri, J Mehnert, A W Silk, S K Jabbour, S Ganesan
ESMO Open. 2022-02-01 - 1208 citationsEndoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword?Jyoti D. Malhotra, Randal J. Kaufman
Antioxidants & Redox Signaling. 2007-11-02
Press Mentions
Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024- BeyondSpring Presents Phase 1 Data on the Anti-Cancer Effect of Plinabulin in Combination with Checkpoint Inhibitors in SCLC at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 24th, 2021
- How Covid Vaccine Diplomacy Is Helping India Win Back Its NeighbourhoodJanuary 15th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
